In human ALS patients, low levels of EPHA4 have been associated with later disease onset and/or a slower disease progression, providing a site for potential therapeutic intervention (Van Hoecke et al., 2012). This evidence concerns the gene EPHA4 and amyotrophic lateral sclerosis.